Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iHuman (IH) Other Accumulated Expenses (2020 - 2025)

iHuman has reported Other Accumulated Expenses over the past 6 years, most recently at $150298.1 for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 81.44% to $150298.1 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $150298.1 through Dec 2025, down 81.44% year-over-year, with the annual reading at $152000.0 for FY2025, 36.13% down from the prior year.
  • Other Accumulated Expenses was $150298.1 for Q4 2025 at iHuman, down from $809678.6 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $1.2 million in Q4 2021 and troughed at $150298.1 in Q4 2025.
  • The 5-year median for Other Accumulated Expenses is $726923.1 (2022), against an average of $703849.4.
  • Biggest five-year swings in Other Accumulated Expenses: surged 128.43% in 2021 and later plummeted 81.44% in 2025.
  • Tracing IH's Other Accumulated Expenses over 5 years: stood at $1.2 million in 2021, then crashed by 36.82% to $726923.1 in 2022, then fell by 6.21% to $681798.2 in 2023, then grew by 18.76% to $809678.6 in 2024, then plummeted by 81.44% to $150298.1 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $150298.1, $809678.6, and $681798.2 for Q4 2025, Q4 2024, and Q4 2023 respectively.